The Challenge of Slowing Diabetic Kidney Disease Progression and Reducing Cardiovascular Risk: Recent Advances and Novel Strategies
Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including targeting mineralocorticoid receptor overactivation with novel, non-steroidal mineralocorticoid receptor antagonists (MRAs). These agents have shown promise in DKD, as demonstrated in recent clinical trial results, with phase III trial results recently announced and also ongoing.
This interactive infographic activity will walk you through the potential role of these novel agents in DKD, including rationale, mechanisms of action, early clinical trials, and phase 3 trials. Included in the activity are also expert feedback and discussions to further elaborate on this information, as well as additional resources and suggested readings.
This activity is also part of the DKD Digital Highlights Hub.
This activity is designed for healthcare professionals, including nephrologists, cardiologists, primary care clinicians (PCPs), pharmacists, nurses, nurse practitioners, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Identify T2DM patients at risk for kidney disease or kidney disease progression.
- Summarize the mechanisms of action of emerging DKD treatments.
- Interpret the latest clinical trial data with emerging treatment options for DKD.
George L. Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Dr. Bakris discloses the following:
Consulting Fees: Merck, Vifor, Ionis, Alynalam, Bayer, Novo Nordisk
Contracted Research: InRegen, KBP Biosciences
Rajiv Agarwal, MD, MS
Professor of Medicine
Indiana University School of Medicine and VA Medical Center
Dr. Agarwal discloses the following:
Salary: Indiana University, VA
Royalty: Up To Date
Consulting Fees: Akebia Therapeutics Inc; Astrazeneca AB; Astrazeneca Pharmaceuticals LP; Bayer Healthcare Pharmaceuticals Inc.; Boehringer Ingelheim B.V.; Boehringer Ingelheim International GMBH
Boehringer Ingelheim Pharma GbmH & Co KG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Ironwood Pharmaceuticals, Inc; Janssen Research & Development, LLC; Relypsa, Inc. Sanofi Vifor Fresenius Medical Care Renal Pharma Ltd.; Merck & Co; Lexicon; Reata
Gerasimos Filippatos, MD, FESC, FHFA, FHFSA(h)
Professor of Cardiology
National and Kapodistrian University of Athens School of Medicine
Dr. Filippatos discloses the following:
Salary: University of Athens
Speakers' Bureaus: Boehringer Ingelheim, Bayer
Committee Member: BI, Bayer, Amgen, Servier, Medtronic
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education.
This is an knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2886-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period July 30, 2021 through July 30, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.